Revenue Surges 23% as da Vinci 5 Placements Accelerate (ISRG Q1 2026 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Intuitive Surgical delivered an exceptionally strong first quarter, demonstrating the compounding clinical value of its expanding robotic ecosystem. Fueled by 17% global procedure growth and rapid customer adoption of the next-generation da Vinci 5 system, the company posted a 23% increase in revenue to $2.77 billion. With momentum building across its Single Port (SP) and Ion platforms, and favorable policy developments emerging in key international markets, management confidently raised its full-year guidance for both procedure growth and gross margins.
Robust Procedure Volume and Capital Placements
Intuitive's core business exhibited broad-based strength, with total procedures growing 17% worldwide. This was underpinned by a 16% increase in da Vinci procedures to 847,000, led by sustained momentum in general surgery across the U.S. and Europe. Capital placement remained robust as the company installed 431 da Vinci systems during the quarter, prominently featuring 232 units of the newly launched da Vinci 5. The rapid uptake of the da Vinci 5, which management noted currently enjoys an 11% utilization premium over the Xi system in the U.S., significantly contributed to the 24% surge in systems revenue.
Expanding Ecosystem: SP and Ion Platforms
Beyond the multi-port da Vinci franchise, Intuitive's targeted platforms delivered impressive growth. The Single Port (SP) platform saw procedures surge 68% year-over-year, driven by geographic expansion in Korea and the U.S., and the successful broad launch of the SP stapler. Meanwhile, the Ion endoluminal system for lung biopsy continued its strong trajectory with procedures increasing 39% to 43,000. Management highlighted recent clinical publications demonstrating Ion's ability to support the earlier identification of lung cancer malignancy, reinforcing the platform's long-term value proposition.
International Dynamics and Policy Tailwinds
International performance was mixed but generally supportive of long-term expansion. While procedure growth outside the U.S. remained strong at 19%, management noted ongoing headwinds in China due to competitive pressures and low tender activity. Conversely, the outlook in Japan improved significantly; the Japanese Ministry of Health, Labor and Welfare introduced incremental reimbursements for high-volume robotic programs and expanded coverage to seven new procedures starting in June 2026. This policy shift is expected to gradually restimulate capital placements and procedural adoption in the region.
Profitability Gains and Raised 2026 Guidance
Financially, Intuitive demonstrated excellent operating leverage. Non-GAAP gross margin expanded to 67.8%, driven by product cost reductions and fixed overhead absorption, which easily offset minor tariff impacts. Consequently, non-GAAP net income reached $901 million, or $2.50 per share. Reflecting this strong start to the year and robust early adoption of new technologies, management raised its full-year 2026 outlook. The company now expects da Vinci procedure growth of 13.5% to 15.5% (up from 13% to 15%) and improved its non-GAAP gross margin forecast to a range of 67.5% to 68.5%.